Eupraxia Pharmaceuticals Inc.
EPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $23 | $20 | $14 | $8 |
| G&A Expenses | $16 | $7 | $4 | $7 |
| SG&A Expenses | $16 | $7 | $4 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $39 | $28 | $18 | $15 |
| Operating Income | -$39 | -$28 | -$18 | -$15 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | -$1 | -$1 | -$4 |
| Pre-Tax Income | -$37 | -$29 | -$19 | -$18 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$37 | -$28 | -$18 | -$18 |
| % Margin | – | – | – | – |
| EPS | -0.76 | -1.17 | -0.96 | -1.61 |
| % Growth | 35% | -21.9% | 40.4% | – |
| EPS Diluted | -0.76 | -1.17 | -0.96 | -1.61 |
| Weighted Avg Shares Out | 34 | 24 | 19 | 14 |
| Weighted Avg Shares Out Dil | 34 | 24 | 19 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$36 | -$28 | -$18 | -$17 |
| % Margin | – | – | – | – |